Merck's stock rose 5% following its Q3 2026 earnings report, which beat analyst expectations with adjusted EPS of $2.49 and revenue of $18.09 billion. The company raised its 2026 adjusted EPS guidance to $2.77-$2.82, driven by strong sales of its cancer drug Keytruda and pulmonary hypertension drug Winrevair. Despite some margin pressure and expected generic competition in 2027, Merck's pipeline, including the sac-TMT antibody-drug conjugate and a late-stage cancer vaccine, offers growth potential. This contrasts with Eli Lilly's faster growth driven by obesity drugs, while Johnson & Johnson benefits from diversification.
Merck's stock gained 5.16% to USD 148.40, nearing its 52-week high of USD 156.43 as of Oct 29, 2026 22:22 WIB on Pluang. Eli Lilly outpaced Merck with a 6.53% rise to USD 1,372.91, reflecting stronger buying interest (71% Buy orders) compared to Merck's balanced 50% Sell/Buy split. Johnson & Johnson edged up 1.61% to USD 275.42, close to its 52-week high of USD 278.43, but with a heavier sell bias at 78% Sell orders on Pluang.
Merck & Co. reported an 8.9% quarter-over-quarter revenue increase in Q3, reaching $18.09 billion and beating analyst estimates. Keytruda and Keytruda Qlex sales grew 5.6% year-over-year to $8.1 billion, while Winrevair sales rose 18% sequentially to...
Merck exceeded third-quarter earnings and revenue expectations, driven by strong sales of its immunotherapy drug Keytruda and its newer injectable form, Qlex, which posted $830 million in sales—the highest since its 2025 launch. The company raised it...
Moderna's stock climbed 4% after strong Phase 3 melanoma vaccine trial results, despite a downgrade from William Blair citing valuation concerns after a 636% yearly gain. The trial showed Moderna and Merck's vaccine reduced melanoma recurrence risk b...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
The global CRISPR market is forecasted to grow from $3.48 billion in 2026 to $6.12 billion by 2031, at a CAGR of 12%. Growth is fueled by expanding use in drug discovery, gene therapy, precision medicine, and agriculture, alongside technological adva...
